Table 3

Anti-MCV, anti-CCP, and IgM-RF at baseline and after 6 and 12 months of infliximab therapy

Response

6 months

Baseline

6 months

Response

12 months

Baseline

12 months


Anti-MCV, U/mL

Responders

(n = 11)

654 (89–2,918)

535 (56–3,000)

Responders

(n = 15)

293 (61–2,918)

117a (48–3,582)

Nonresponders

(n = 12)

307 (60–1,145)

227 (40–1,234)

Nonresponders

(n = 8)

363 (60–1,145)

227 (47–1,500)

Anti-CCP, U/mL

Responders

(n = 11)

1,402 (83–11,360)

1,300 (54–11,370)

Responders

(n = 15)

1,246 (83–11,360)

837b (48–12,640)

Nonresponders

(n = 12)

962 (130–4,232)

1,134 (74–2,392)

Nonresponders

(n = 8)

1,169 (275–4,232)

1,331 (126–4,313)

IgM-RF, IU/mL

Responders

(n = 11)

91.5 (10–424)

58 (10–216)

Responders

(n = 15)

74.5 (9–781)

49.5c (10–214)

Nonresponders

(n = 12)

205 (9–949)

133c (10–367)

Nonresponders

(n = 8)

283 (14–949)

152c (35–463)


Values are expressed as median (range), and the nonparametric Wilcoxon signed rank test was used for paired comparisons of changes in anti-CCP and anti-MCV titres between responders and nonresponders. aP < 0.01 versus baseline; bP < 0.05 versus baseline; cP = 0.02 versus baseline. Anti-CCP, anti-cyclic citrullinated peptide antibody; anti-MCV, anti-mutated vimentin citrullinated antibody; RF, rheumatoid factor.

Nicaise Roland et al. Arthritis Research & Therapy 2008 10:R142   doi:10.1186/ar2570

Open Data